Ajinomoto to manufacture COVID-19 drug for Humanigen

By The Science Advisory Board staff writers

May 27, 2020 -- Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab. The drug is being studied in a phase III clinical trial for adult patients hospitalized with COVID-19.

Under the agreement, Ajinomoto will provide drug product aseptic fill-finish services for Humanigen at its San Diego, CA facility.

Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody. The drug neutralizes a key cytokine in the initiation of a cytokine storm, a known factor in COVID-19 complications.

As part of the randomized, placebo-controlled, double-blinded phase III study, the drug is being administered in multiple locations across the U.S.

AbCellera raises $105M to fund antibody drug development
Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity...
Abcore develops antibodies against COVID-19
Antibody research and development firm Abcore said that it's discovered and tested a panel of functional therapeutic candidates for the treatment of COVID-19.
SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines,...
Yumab identifies COVID-19 antibody therapy
German biotechnology company Yumab said it has identified a promising candidate for COVID-19 antibody therapy.

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
BioProcess International
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter